仁度生物(688193) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥38,766,500.34, representing a decrease of 58.44% compared to the same period last year[5]. - The net profit attributable to shareholders was a loss of ¥6,392,335.66, reflecting a decline of 138.03% year-over-year[5]. - Basic and diluted earnings per share were both -¥0.16, down 128.57% from the same period last year[6]. - Total operating revenue for Q1 2023 was ¥38,766,500.34, a decrease of 58.5% compared to ¥93,280,166.18 in Q1 2022[20]. - Net profit for Q1 2023 was a loss of ¥6,392,335.66, compared to a profit of ¥16,806,634.77 in Q1 2022, representing a significant decline[20]. - The company experienced a comprehensive loss of ¥6,909,010.22 in Q1 2023, compared to a comprehensive income of ¥16,784,019.05 in Q1 2022[21]. Cash Flow and Liquidity - The net cash flow from operating activities was negative at ¥6,213,384.20, a decrease of 204.23% compared to the previous year[6]. - In Q1 2023, the net cash flow from operating activities was -$6,213,384.20, a significant decline from $5,961,279.66 in Q1 2022[24]. - Total cash inflow from operating activities was $67,228,828.74, down from $74,655,779.92 in the same quarter last year, representing a decrease of approximately 10.5%[24]. - Cash outflow from operating activities increased to $73,442,212.94 from $68,694,500.26, marking an increase of about 6.5% year-over-year[24]. - The total cash and cash equivalents at the end of Q1 2023 were $273,236,061.29, down from $875,430,465.48 at the end of Q1 2022, reflecting a decrease of approximately 68.9%[25]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,066,374,019.29, a decrease of 2.05% from the end of the previous year[6]. - Total liabilities decreased to ¥110,652,691.07 in Q1 2023 from ¥127,337,004.79 in Q1 2022, indicating a reduction of 13.1%[17]. - The company's total assets as of Q1 2023 were ¥1,066,374,019.29, a decrease from ¥1,088,721,710.38 in the previous year[17]. Research and Development - Research and development expenses totaled ¥8,518,167.13, an increase of 17.21% year-over-year, accounting for 21.97% of operating revenue, up 12.35 percentage points[6]. - Research and development expenses increased to ¥8,518,167.13 in Q1 2023, up from ¥7,267,729.68 in Q1 2022, reflecting a focus on innovation[20]. - The company is accelerating multiple ongoing projects to enhance future growth potential, which contributed to the increase in R&D expenses[9]. Shareholder Information - The top shareholder,居金良, holds 19.65% of the shares with a total of 7,858,357 shares[12]. - MING LI INVESTMENTS LIMITED is the second-largest shareholder with 15.44%, holding 6,176,624 shares[12]. - The company has a total of 10 major shareholders, with the top 10 holding significant stakes in the company[13]. Operational Insights - The decline in revenue was attributed to a significant drop in pandemic-related testing products, despite a recovery in routine testing reagent business[9]. - The report indicates no significant changes in the company's operational strategies or new product developments during the quarter[14]. - The company has not provided specific guidance for future performance or market expansion plans in this report[14].